Created at	Source	Raw Value	Validated value
Nov. 26, 2021, 10:30 p.m.	oms	Known hypersensitivity to immunoglobulin. <br/ >History or presence of any disorder that increases the safety risk of the patient as per investigator discretion. <br/ >History of DVT, PE, thromboembolic stroke or other thrombotic events. <br/ >Active participant in another research treatment study. <br/ >Pregnancy. <br/ >	Known hypersensitivity to immunoglobulin. <br/ >History or presence of any disorder that increases the safety risk of the patient as per investigator discretion. <br/ >History of DVT, PE, thromboembolic stroke or other thrombotic events. <br/ >Active participant in another research treatment study. <br/ >Pregnancy. <br/ >
Nov. 13, 2021, 5:33 p.m.	oms	N/A	N/A
May 27, 2021, 12:45 a.m.	oms	Known hypersensitivity to immunoglobulin. <br/ >History or presence of any disorder that increases the safety risk of the patient as per investigator discretion. <br/ >History of DVT, PE, thromboembolic stroke or other thrombotic events. <br/ >Active participant in another research treatment study. <br/ >Pregnancy. <br/ >	Known hypersensitivity to immunoglobulin. <br/ >History or presence of any disorder that increases the safety risk of the patient as per investigator discretion. <br/ >History of DVT, PE, thromboembolic stroke or other thrombotic events. <br/ >Active participant in another research treatment study. <br/ >Pregnancy. <br/ >